Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.49720
Abstract: Key Points Question Does targeting MUC5AC with the NPC-1C antibody augment the antitumor activity of gemcitabine plus nab-paclitaxel as a second-line treatment for pancreatic cancer? Findings In this randomized phase 2 trial of 78 patients… read more here.
Keywords: nab paclitaxel; advanced pancreatic; line; line gemcitabine ... See more keywords
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.5041
Abstract: Importance Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy. Objective To determine the association of toxic… read more here.
Keywords: advanced melanoma; patients advanced; management; line ... See more keywords
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2024 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2024.0207
Abstract: Key Points Question Are combinations of FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus anti–PD-L1 with or without anti–cytotoxic T-lymphocyte associated protein 4 (CTLA4) in second-line treatment of advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma effective? Findings… read more here.
Keywords: adenocarcinoma; advanced gastric; line treatment; gastric gastroesophageal ... See more keywords
SALIRI‐based (raltitrexed plus irinotecan) therapy as a second‐line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non‐interventional, registry study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Communications"
DOI: 10.1002/cac2.12586
Abstract: Primary chemotherapy options for colorectal cancer (CRC) involve four key drugs: fluorouracils (5-FU), oxaliplatin, irinotecan and raltitrexed. The first-line regimen consists of 5-FU and leucovorin combined with oxaliplatin (FOLFOX), while the second-line regimen involves 5-FU… read more here.
Keywords: colorectal cancer; treatment; non interventional; second line ... See more keywords
Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5053
Abstract: Currently there is no standard therapy recommended for second‐line treatment for thymic carcinoma. Our study compared multidrug chemotherapy, single‐agent chemotherapy, and PD‐1 inhibitors in patients diagnosed with advanced thymic carcinoma who had previous platinum‐based chemotherapy… read more here.
Keywords: advanced thymic; thymic carcinoma; line treatment; second line ... See more keywords
Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5143
Abstract: Few therapeutic options are approved as second‐line treatment after failure of platinum‐based chemotherapy for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Topotecan widespread use remains challenged by the risk of severe toxicities in a pretreated… read more here.
Keywords: lung cancer; small cell; line; second line ... See more keywords
Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5440
Abstract: Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers… read more here.
Keywords: cell; metastatic squamous; first line; line ... See more keywords
Perampanel as a second‐line therapy to midazolam reduces soman‐induced status epilepticus and neurodegeneration in rats
Sign Up to like & getrecommendations! Published in 2025 at "Epilepsia Open"
DOI: 10.1002/epi4.70083
Abstract: A benzodiazepine (diazepam or midazolam) is one of the current standards of care therapies to effectively terminate organophosphorus nerve agent‐induced status epilepticus when administered shortly after onset. Preclinical studies showed that benzodiazepines were less effective… read more here.
Keywords: induced status; status epilepticus; status; second line ... See more keywords
Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5‐fluorouracil and leucovorin combination as first‐ or second‐line treatment against metastatic colorectal cancer: Results from the International EORTC 05011 Trial
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33422
Abstract: The triplet combination of irinotecan, oxaliplatin and fluorouracil is an active frontline regimen in metastatic colorectal cancer, but scarce data exist on its use as salvage treatment. We aimed at assessing its safety and efficacy… read more here.
Keywords: metastatic colorectal; line; treatment; colorectal cancer ... See more keywords
Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Cancer"
DOI: 10.1002/ijc.34894
Abstract: FOLFOX plus nivolumab represents a standard of care for first‐line therapy of advanced gastroesophageal cancer (aGEC) with positive PD‐L1 expression. The efficacy of second‐line VEGFR‐2 inhibition with ramucirumab (RAM) plus chemotherapy after progression to immunochemotherapy… read more here.
Keywords: ram; line therapy; first line; second line ... See more keywords
Suboptimal immune recovery and associated factors among people living with HIV/AIDS on second‐line antiretroviral therapy in central China: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Virology"
DOI: 10.1002/jmv.27944
Abstract: The introduction and scale‐up of antiretroviral therapy (ART) have contributed to significantly improved patients with acquired immune deficiency syndrome (AIDS) quality of life and prolongs their survival. This has occurred by suppressing viral replication and… read more here.
Keywords: cell count; line art; cd4 cell; line ... See more keywords